Proactive analyst Daniel Appiah analyses SourceBio International and explains why there is much more to the business than just its PCR test, even though that has been a huge driver over the past two years.
Indeed, cash generated during Covid is setting the business up for years to come, says Appiah, especially in genomics and health diagnostics, where the NHS has a huge backlog of work due to the pandemic.